Century Therapeutics' CNTY-101, an iPSC-derived CD19 CAR-iNK cell therapy, will be assessed in a Phase 1/2 trial for B-cell mediated autoimmune diseases.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.